Download Files:
Veliflapon
$250 – $2,050
Products Details
Product Description
– Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor[1]. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4[2].
Web ID
– HY-14165
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C23H23NO3
References
– [1]Hatzelmann A, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994 Nov;43(1-2):64-8.|[2]Müller-Peddinghaus R, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267(1):51-7.|[3]Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.|[4]Jawień J, et al. BAY x 1005 attenuates atherosclerosis in apoE/LDLR – double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
CAS Number
– 128253-31-6
Molecular Weight
– 361.43
Compound Purity
– 99.48
SMILES
– O=C(O)[C@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3
Clinical Information
– Phase 3
Research Area
– Inflammation/Immunology; Cardiovascular Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– FLAP;Leukotriene Receptor
Isoform
– LTB4;LTC4
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
